Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.57 |
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.35 |
| ▸ | FABP3 | P05413 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225216 | 0.90 | S1PR1 (0.69) | S1PR1S1PR5LMNAMAPTRXFP1 | |
| SCHEMBL2222274 | 0.86 | S1PR1 (0.61) | S1PR1LMNAMAPTRXFP1 | |
| SCHEMBL14797138 | 0.85 | FFAR4 (0.46) | S1PR1FFAR4S1PR5KCNH2FFAR1 | |
| SCHEMBL2225593 | 0.85 | S1PR1 (0.52) | S1PR1LMNAMAPTRXFP1 | |
| SCHEMBL2224059 | 0.84 | S1PR1 (0.51) | S1PR1CYP3A4LMNAMAPTRXFP1 | |
| SCHEMBL14797187 | 0.83 | S1PR1 (0.51) | S1PR1LMNAMAPTRXFP1 | |
| SCHEMBL14797050 | 0.83 | S1PR1 (0.67) | S1PR1FFAR4S1PR5LMNAMAPT | |
| SCHEMBL14797105 | 0.83 | S1PR1 (0.65) | S1PR1FFAR1 | |
| SCHEMBL14796982 | 0.83 | S1PR1 (0.67) | S1PR1LMNAMAPTRXFP1FFAR1 | |
| SCHEMBL14797108 | 0.83 | S1PR1 (0.70) | S1PR1LMNAMAPTRXFP1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846692-B2 | Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring | SANOFI (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20130079358-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI (FR) | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079358-A1 | CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | OXGR1, EDNRA, EDF1 | S1PR1 129/4885FFAR4 61/4885S1PR5 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.